Capri­cor hits pri­ma­ry end­point in Duchenne ex­ten­sion study, ready­ing its FDA pitch

It has been a very bumpy ride for Capri­cor Ther­a­peu­tics over the past sev­er­al years, in­clud­ing a halt­ed J&J part­ner­ship and ven­ture in­to pen­ny stock sta­tus. How­ev­er, the lat­est news from the San Diego-based biotech shows that its ex­per­i­men­tal Duchenne drug may be a durable, long-term treat­ment.

The com­pa­ny post­ed the one-year re­sults from its open-la­bel ex­ten­sion study for their can­di­date dubbed CAP-1002. The ex­ten­sion from its Phase II study, named HOPE-2, was con­duct­ed in boys and young men with lat­er-stage Duchenne mus­cu­lar dy­s­tro­phy who paused and then re­sumed treat­ment af­ter a year. Re­searchers mea­sured pa­tients in the one-year fol­low-up against the orig­i­nal study’s treat­ment arm ef­fect and in two sub­sets of the orig­i­nal place­bo group.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER